【摘要】：新的戰(zhàn)場(chǎng)救治更強(qiáng)調(diào)“醫(yī)療與士兵同在”,而戰(zhàn)場(chǎng)上醫(yī)療的第一原則是救命,生命復(fù)蘇。臨床研究進(jìn)一步評(píng)價(jià)了傳統(tǒng)的復(fù)蘇藥物和方法在臨床應(yīng)用中的實(shí)際效果,如腎上腺素與血管加壓素復(fù)蘇效果的比較,利多卡因不再作為預(yù)防性用藥使用于急性心肌梗死中,胺碘酮經(jīng)大規(guī)模臨床研究被證實(shí)為心衰患者和對(duì)除顫及腎上腺素?zé)o效的心臟停搏患者的首選用藥。限制性液體復(fù)蘇概念重新審視了以住對(duì)失血性休克的快速補(bǔ)液療法,晶體液、膠體液和高滲鹽水對(duì)危重和創(chuàng)傷患者應(yīng)用的利弊仍需臨床研究探討。
[Abstract]:New battlefield care emphasizes "medical care with soldiers", and the first principle of battlefield medical care is life-saving and life recovery. Clinical studies have further evaluated the practical effects of traditional resuscitation drugs and methods, such as epinephrine and vasopressin, and lidocaine is no longer used as a preventive drug in acute myocardial infarction. Amiodarone has been proven to be the first choice for patients with heart failure and cardiac arrest with no effect on defibrillation and epinephrine by large-scale clinical studies. The concept of restricted fluid resuscitation reexamined the advantages and disadvantages of rapid fluid replacement therapy for hemorrhagic shock, crystalloid, colloid and hypertonic saline for critical and traumatic patients.
【作者單位】： 解放軍總醫(yī)院急診科
【分類號(hào)】：R82

【相似文獻(xiàn)】

相關(guān)期刊論文 前2條

1 沈洪;常用復(fù)蘇藥物和方法的臨床應(yīng)用評(píng)價(jià)[J];解放軍醫(yī)學(xué)雜志;2005年07期

2 汪新良;謝鋼;鄭偉華;寧曄;蔣崇慧;;限制與積極液體復(fù)蘇法救治創(chuàng)傷失血性休克的療效比較[J];中國(guó)急救醫(yī)學(xué);2005年12期

，

本文編號(hào)：2462098